In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Intellia Therapeutics Inc’s stock clocked out at $9.55, up 1.92% from its previous closing price of $9.37. In other words, the price has increased by $1.92 from its previous closing price. On the day, 3.06 million shares were traded. NTLA stock price reached its highest trading level at $9.67 during the session, while it also had its lowest trading level at $9.25.
Ratios:
To gain a deeper understanding of NTLA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 11, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8. JP Morgan Downgraded its Neutral to Underweight on November 07, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when LEONARD JOHN M bought 88,146 shares for $9.33 per share.
Schultes Birgit C sold 31 shares of NTLA for $539 on Oct 01 ’25. The EVP, Chief Scientific Officer now owns 105,184 shares after completing the transaction at $17.38 per share. On Oct 01 ’25, another insider, Dube Michael P, who serves as the VP, Chief Accounting Officer of the company, sold 1,871 shares for $17.38 each. As a result, the insider received 32,518 and left with 55,266 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1106175872 and an Enterprise Value of 693097792. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.23 while its Price-to-Book (P/B) ratio in mrq is 1.48. Its current Enterprise Value per Revenue stands at 12.048 whereas that against EBITDA is -1.479.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.06, which has changed by -0.25968993 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.25, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -35.71%, while the 200-Day Moving Average is calculated to be -15.87%.
Shares Statistics:
It appears that NTLA traded 7.96M shares on average per day over the past three months and 3967700 shares per day over the past ten days. A total of 115.79M shares are outstanding, with a floating share count of 109.90M. Insiders hold about 5.12% of the company’s shares, while institutions hold 86.29% stake in the company. Shares short for NTLA as of 1764288000 were 44572813 with a Short Ratio of 5.60, compared to 1761868800 on 39075621. Therefore, it implies a Short% of Shares Outstanding of 44572813 and a Short% of Float of 43.169999999999995.
Earnings Estimates
Its stock is currently analyzed by 18.0 different market analysts. The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.89 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.8 and -$4.11 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$3.6, with 21.0 analysts recommending between -$1.96 and -$4.41.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $68.3M, while the lowest revenue estimate was $44.65M, resulting in an average revenue estimate of $56.86M. In the same quarter a year ago, actual revenue was $57.88M
